<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564811</url>
  </required_header>
  <id_info>
    <org_study_id>upeclin/HC/FMB-Unesp-03</org_study_id>
    <nct_id>NCT00564811</nct_id>
  </id_info>
  <brief_title>Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)</brief_title>
  <official_title>Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom) on the Nutritional State and Liver Biochemistry in Hepatitis C Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UPECLIN HC FM Botucatu Unesp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UPECLIN HC FM Botucatu Unesp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to verify the influence of Agaricus blazei (Murrill) ss. Heinemann
      (A. blazei) on the evolution of nutritional state and liver function in hepatitis C patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten patients were studied (5 - GI - not taking A. blazei - and 5 - G2 - taking A. blazei),
      from both sexes, with positive Anti-VHC and a healthy nutritional state, admitted into in the
      viral hepatitis ward. Diagnosis and treatment for hepatitis C concurred with the regulations
      of the Ministry of Health and nutritional evaluation was performed in 3 moments according to
      anthropometrical, bioimpedance, biochemical and dietary standards, with duration of 6 months.
      The consumption of A. blazei (10g/day) in dehydrated powder was concomitant with antiviral
      therapy (conventional or pegylated interferon associated with ribavirin) with duration of 5
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: influence of Agaricus blazei (Murrill) ss. Heinemann on the evolution of nutritional state and liver function in hepatitis C patients. Time Frame: six months</measure>
    <time_frame>Time Frame: six months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Nutritional Status</condition>
  <condition>Hepatitis, Viral, Human</condition>
  <arm_group>
    <arm_group_label>G1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>G2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)</intervention_name>
    <description>Agaricus blazei powder, 10 grams/day, for 5 months</description>
    <arm_group_label>G2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To have been informed and signed adequately the free and clarified assent

          -  Initiating the anti-viral treatment (interferon or pegylated interferon associate the
             ribavirin)

          -  Age: 24-70 years

          -  Gender :both the gender

          -  Race : all races

          -  To present serology positive to the anti-VHC ELISA

          -  To present genotype type 1,2,or 3

          -  Body mass index- &gt;18,5 e &lt; 35kg /m2

          -  Conditions full to the ORAL ingestion

        Exclusion Criteria:

          -  Don't agree to the project or don't have signed the term of clarified free assent

          -  Restriction for oral ingestion

          -  The existence of surface of antigen of the hepatitis B virus(Ag HBs)

          -  The existence of antibody for the human immunodeficiency virus

          -  To be enclosed in another project of research or form of treatment

          -  Pregnant women

          -  Suckles

          -  Cirrhosis

          -  Patients with hepatitis auto-imune.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caramori A Carlos, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Botucatu Medicine School - Sao Paulo State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Internal Medicine Department, Botucatu School of Medicine, SÃ£o Paulo State University - UNESP</name>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <zip>18618-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2007</study_first_submitted>
  <study_first_submitted_qc>November 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2007</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <keyword>Agaricus blazei (Murrill) ss. Heinemann,</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Nutritional status</keyword>
  <keyword>Liver Function Tests</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Viral, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

